Next-generation Stroke Device integrates Protective Cover
Lazarus Effect, a medical device company focused on improving treatment of acute ischemic stroke through effective removal of the blood clots that cause a stroke, announced that the Lazarus ReCover™ Thrombectomy Device has received CE Mark. The Lazarus ReCover is a next-generation ischemic stroke device that addresses a major limitation of stent-based clot retrieval, the current gold-standard technology for clot removal, by integrating a protective cover intended to prevent clot fragmentation or embolism and the potential for secondary stroke.
Lazarus Effect plans to launch the Lazarus ReCover in Europe during Q1 2013. The company is currently evaluating distribution partners.
Stent-based thrombectomy (clot removal) devices have demonstrated success "capturing" clots within the affected vessel, but often lose thrombus as the device is extracted. Among 124 Solitaire™ stent retriever cases evaluated during a recent European study, lost clot pieces traveled into an area of the brain previously not affected nine percent of the time, causing new areas of brain to experience stroke.
The ReCover device comprises a nitinol wire-wrapped stent with a highly visible, radio-opaque core and a nitinol mesh cover that surrounds the stent and thrombus during retrieval to help prevent clot fragmentation and embolization.
"The Lazarus ReCover is a significant advancement in the stent-based retriever category," said Martin Dieck, chairman and CEO, Lazarus Effect. "By integrating protection directly onto the proven stent retriever design, Lazarus Effect has reduced the number of devices that may be needed for the procedure, decreasing complexity and saving critical time while simultaneously creating a device that should be more effective at preventing thrombus loss during removal."
Approximately two million strokes occur in Europe each year. Seventy-eight percent of these are ischemic and caused by a dislodged blood clot or arterial plaque debris traveling to the brain and blocking a cerebral artery.
"In the past few years we have seen a dramatic increase in the number of ischemic strokes treated in Europe. This is partly due to treatment centers experiencing improved recanalization rates with stent retrievers," said J Mocco, MD, MS, FAHA, FAANS, a leading stroke interventionalist and the principal investigator of THERAPY, an international randomized stroke trial. "However, there are still serious concerns over the loss of thrombus during clot retrieval. The ReCover device offers innovative, easy-to-use technology designed to address these concerns and thereby improve patient outcomes."
Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment with the ReCover.
About Lazarus Effect
Lazarus Effect is generating a complete portfolio of products to treat ischemic stroke based on a patent-pending wire-frame technology platform. The company's founders are proven pioneers of ischemic stroke treatment with significant involvement in every aspect of the ischemic stroke business, technology and treatment. More information can be found at www.lazarus-effect.com.
- TOP Medical signs Distribution Agreement with Myelotec
- Direct Flow Medical Demonstrate Excellent Outcomes at Six Months
- Tryton Medical Announces First Results From Pivotal Study
- TOP Medical Celebrates 10th Anniversary
- Direct Flow Medical Demonstrates Excellent 30 Day Outcomes
- Demonstr8 Randomized Trial Shows Excellent Results For Cre8 Drug Eluting Stent
- Tryton Side Branch SHORT enable physicians to treat complex bifurcations in a straightforward manner
- Kimberly- Clark Cooled RF Workshop for Chronic Pain Management- 4 June-AMC Amsterdam
- TOP Medical at PCR 2013!
- Studies demonstrate effectiveness of minimally-invasive cooled radiofrequency treatment for low-back pain
- Cooled RF therapies SInergy and TransDiscal included in Dutch multi-center protocol
- TOP Medical signs Distribution Agreement for the Next Generation Stroke Retrieval Device
- TOP Medical signs Distribution Agreement with Direct Flow Medical
- TOP Medical hires Director for Belgium & Luxembourg
- Next-generation TAVR tools aim for Precise Placement
- Next-generation Stroke Device integrates Protective Cover
- TOP Medical hires Stan Verwer
- S-ICD has won FDA approval
- TOP Medical expands and is looking for two new employees!
- TOP Medical Honored with Asahi Intecc Recognition
- Drs. R.E. Knops receives To Optimize Performance Award for 100 Cameron Health S-ICD Implantations
- TOP Medical moved into New Facility
- Covidien acquires OneShot Ablation System of Maya Medical
- Butterfly Foundation in Nepal opens Health Clinic supported by TOP Medical
- UMC Utrecht to start Study with Cre8 Polymer-free Drug Eluting Stent
- Cre8 Polymer Free, the Effective DES Solution with No Safety Concerns
- Boston Scientific to Acquire Cameron Health
- TOP Medical to expand its business in brand new facility
- TOP Medical receives award for Outstanding Performances in 2011
- TOP Medical to attend Complex PCI, Left Main and CTO Summit in New York
- TOP Medical to Launch the Cre8 Polymerfree Drug Eluting Stent
- TOP Medical to sell Kimberly-Clark Pain Management Product Line
- Direct Flow Medical receives CE Mark
- Cameron Health announced 1,000th S-ICD Implant
- TOP Medical expands business with new Neuro Therapies Division
- Study shows that Baylis RF Needle Improves Safety and Efficacy of Transseptal Puncture
- TOP Medical signs exclusive agreement with Toray International to distribute the Inoue-Balloon
- TOP Medical launches the ASAHI SION, a New Generation Workhorse Wire with a 3D Torque Revolution
- Tryton Announces CE Mark for Larger-Diameter Sizes of Side Branch Stent.
- TOP Medical Finished in New York City Marathon